IMPACT Therapeutics Concludes Stabilization; 6.30 Million H Shares Allotted at HK$20.10 Each

Bulletin Express

Jun 08

IMPACT Therapeutics, Inc. (IMPACT Therapeutics) announced the completion of its post-listing stabilization period on 7 June 2026, exactly 30 days after the close of the Hong Kong Public Offering.

During the stabilization window, Goldman Sachs (Asia) L.L.C., acting as Stabilizing Manager, executed two principal actions:

1. Over-allocations: 6.30 million H shares—equivalent to approximately 15% of the original Global Offering size—were over-allocated in the International Offering. 2. Over-allotment Option: On 5 June 2026, the Overall Coordinators fully exercised the over-allotment option for the same 6.30 million H shares at an offer price of HK$20.10 per share (before brokerage, SFC levy, Stock Exchange trading fee and AFRC levy). These shares were used to settle delayed delivery commitments with placees.

No on-market purchases or sales were conducted for price-stabilization purposes throughout the period.

Following the full exercise of the over-allotment option, IMPACT Therapeutics confirmed that its public float remains in compliance with Listing Rule 19A.28B(1).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1179114095"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1179114095\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1179114095?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-08 17:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179114095","market":"us","top_or_hot":-1,"title":"IMPACT Therapeutics Concludes Stabilization; 6.30 Million H Shares Allotted at HK$20.10 Each","media":"Bulletin Express","content":"<p>IMPACT Therapeutics, Inc. (IMPACT Therapeutics) announced the completion of its post-listing stabilization period on 7 June 2026, exactly 30 days after the close of the Hong Kong Public Offering.</p>\n<p>During the stabilization window, Goldman Sachs (Asia) L.L.C., acting as Stabilizing Manager, executed two principal actions:</p>\n<p>1. Over-allocations: 6.30 million H shares—equivalent to approximately 15% of the original Global Offering size—were over-allocated in the International Offering.  \n2. Over-allotment Option: On 5 June 2026, the Overall Coordinators fully exercised the over-allotment option for the same 6.30 million H shares at an offer price of HK$20.10 per share (before brokerage, SFC levy, Stock Exchange trading fee and AFRC levy). These shares were used to settle delayed delivery commitments with placees.</p>\n<p>No on-market purchases or sales were conducted for price-stabilization purposes throughout the period.</p>\n<p>Following the full exercise of the over-allotment option, IMPACT Therapeutics confirmed that its public float remains in compliance with Listing Rule 19A.28B(1).</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>IMPACT Therapeutics Concludes Stabilization; 6.30 Million H Shares Allotted at HK$20.10 Each</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIMPACT Therapeutics Concludes Stabilization; 6.30 Million H Shares Allotted at HK$20.10 Each\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-08 17:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>IMPACT Therapeutics, Inc. (IMPACT Therapeutics) announced the completion of its post-listing stabilization period on 7 June 2026, exactly 30 days after the close of the Hong Kong Public Offering.</p>\n<p>During the stabilization window, Goldman Sachs (Asia) L.L.C., acting as Stabilizing Manager, executed two principal actions:</p>\n<p>1. Over-allocations: 6.30 million H shares—equivalent to approximately 15% of the original Global Offering size—were over-allocated in the International Offering.  \n2. Over-allotment Option: On 5 June 2026, the Overall Coordinators fully exercised the over-allotment option for the same 6.30 million H shares at an offer price of HK$20.10 per share (before brokerage, SFC levy, Stock Exchange trading fee and AFRC levy). These shares were used to settle delayed delivery commitments with placees.</p>\n<p>No on-market purchases or sales were conducted for price-stabilization purposes throughout the period.</p>\n<p>Following the full exercise of the over-allotment option, IMPACT Therapeutics confirmed that its public float remains in compliance with Listing Rule 19A.28B(1).</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"07630","symbol_name":"英派药业-B","start_time":0,"source_url":"","article_id":"1179114095","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179114095","pubTimestamp":1780909380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"IMPACT Therapeutics, Inc. (IMPACT Therapeutics) announced the completion of its post-listing stabilization period on 7 June 2026, exactly 30 days after the close of the Hong Kong Public Offering....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"07630":"英派药业-B"},"translate_title":"IMPACT Therapeutics得出稳定结论；按每股20.10港元配发630万股H股","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"07630":1},"content_text":"IMPACT Therapeutics, Inc. (IMPACT Therapeutics) announced the completion of its post-listing stabilization period on 7 June 2026, exactly 30 days after the close of the Hong Kong Public Offering.\nDuring the stabilization window, Goldman Sachs (Asia) L.L.C., acting as Stabilizing Manager, executed two principal actions:\n1. Over-allocations: 6.30 million H shares—equivalent to approximately 15% of the original Global Offering size—were over-allocated in the International Offering.  \n2. Over-allotment Option: On 5 June 2026, the Overall Coordinators fully exercised the over-allotment option for the same 6.30 million H shares at an offer price of HK$20.10 per share (before brokerage, SFC levy, Stock Exchange trading fee and AFRC levy). These shares were used to settle delayed delivery commitments with placees.\nNo on-market purchases or sales were conducted for price-stabilization purposes throughout the period.\nFollowing the full exercise of the over-allotment option, IMPACT Therapeutics confirmed that its public float remains in compliance with Listing Rule 19A.28B(1).","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}